You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2025

AbstractFullPdf
Nov 2021519525121
Dec 202125325577
Jan 202220020577
Feb 202218218565
Mar 202221223362
Apr 202220220779
May 202222322956
Jun 202223224292
Jul 202225525872
Aug 202227827956
Sep 202225125775
Oct 202224225254
Nov 202226126471
Dec 202216016035
Jan 202321322268
Feb 202328128291
Mar 202324825448
Apr 202324724871
May 202328228788
Jun 202323323559
Jul 202317717841
Aug 202320720952
Sep 202318118270
Oct 202321821886
Nov 202320520653
Dec 202314014038
Jan 2024989944
Feb 202416716848
Mar 202433634163
Apr 202425225255
May 202421021052
Jun 202420420956
Jul 202422222351
Aug 202418118043
Sep 202413113347
Oct 202420620775
Nov 202417018167
Dec 202420220668
Jan 202520720882
Feb 202524224664
Mar 202520720758
Apr 202521221284
May 202511211265
Jun 202512012247
Jul 2025220
Sep 2025110
Total958497312826